Talk:Pfizer/Archives/2016

Bextra in the lede
I'm not sure if there is a good reason for the Bextra issue to be in the lede of this article. Moreover it occupies around 30% of the lede's total content. The topic isn't anymore lede-worthy than, say, the recent sale of Zoetis. It certainly isn't more lede-worthy than the fact that Pfizer produced Lipitor, the most popular pharmaceutical drug ever -- Lipitor is only mentioned once in the lede fleetingly in the context of a list of other Pfizer drugs. To me, the Bextra suit should be moved in entirety to the Promotional practices section, or, at the very least, it should be reduced to one sentence, an entirely appropriate length for a mention in the intro. ask123 (talk) 19:26, 28 January 2014 (UTC)
 * I've restored the first sentence of it. It had been moved to a new section apparently by mistake (https://en.wikipedia.org/w/index.php?title=Pfizer&diff=692488628&oldid=692486622) as it was already in the "Promotional practices" section. There's similar content in the GlaxoSmithKline article. Peter James (talk) 09:58, 2 May 2016 (UTC)